CompareMarketResearchRequest a sample
Home / Healthcare / Pharmaceutical Omega-3 API

Healthcare · Market report

Pharmaceutical Omega-3 API Market Size, Share and Forecast 2026-2036

The global pharmaceutical omega-3 API market is worth USD 546 mn in 2026 and is forecast to reach USD 933 mn by 2036, growing at a 5.5% CAGR. United States is the largest country market and EPA ethyl ester is the largest by product segment.

USD 546 mnMarket size 2026
USD 933 mnForecast 2036
5.5%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global pharmaceutical omega-3 API market is worth USD 546 mn in 2026 and is forecast to reach USD 933 mn by 2036, growing at a 5.5% CAGR. United States is the largest country market and EPA ethyl ester is the largest by product segment.

ScopeHighly purified EPA and DHA omega-3 active ingredients, in ethyl ester, triglyceride and free fatty acid forms, sold to makers of prescription omega-3 drugs and clinical lipid emulsions.
IndustryHealthcare
Value 2025USD 520 mn
Value 2026USD 546 mn
Value 2036USD 933 mn
CAGR 2026-20365.5%
Volume 2026836 tonnes
Volume 20361,358 tonnes
Average price 2026USD 653,200 per tonne
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Pharmaceutical Omega-3 API market size and forecast, 2026-2036

Exhibit 1The global pharmaceutical omega-3 API market is forecast to grow from USD 546 mn in 2026 to USD 933 mn by 2036, a rise of 71%Global market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 5.5%
Pharmaceutical Omega-3 API market value, 2025 to 2036Market value by year. 2025: USD 520 mn; 2026: USD 546 mn; 2027: USD 576 mn; 2028: USD 608 mn; 2029: USD 641 mn; 2030: USD 676 mn; 2031: USD 714 mn; 2032: USD 753 mn; 2033: USD 794 mn; 2034: USD 838 mn; 2035: USD 884 mn; 2036: USD 933 mn. Compound annual growth rate 2026 to 2036: 5.5%.2025546 mn2026714 mn2031933 mn20365.5% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 546 mn
2027USD 576 mn
2028USD 608 mn
2029USD 641 mn
2030USD 676 mn
2031USD 714 mn
2032USD 753 mn
2033USD 794 mn
2034USD 838 mn
2035USD 884 mn
2036USD 933 mn

Pharmaceutical Omega-3 API market segmentation

By product

Exhibit 2EPA ethyl ester is the largest segment by product, with 36.0% of 2026 revenueEstimated share of 2026 global revenue, by product
Pharmaceutical Omega-3 API market share by product, 2026Share of 2026 revenue by product. EPA ethyl ester: 36.0%; EPA plus DHA ethyl ester: 34.0%; Triglyceride and free acid forms: 18.0%; DHA-only grades: 12.0%.EPA ethyl ester36.0%EPA plus DHA ethyl ester34.0%Triglyceride and free acid forms18.0%DHA-only grades12.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
EPA ethyl ester36.0%42.0%USD 197 mn7.1%
EPA plus DHA ethyl ester34.0%27.2%USD 186 mn3.2%
Triglyceride and free acid forms18.0%19.1%USD 98 mn6.2%
DHA-only grades12.0%11.6%USD 66 mn5.2%

By end use

Exhibit 3Prescription omega-3 drugs adds the most revenue by end use, growing from USD 393 mn in 2026 to USD 650 mn by 2036Estimated revenue in USD by end use, 2026 and 2036 forecast
Pharmaceutical Omega-3 API market by end use, 2026 and 2036Revenue by end use in 2026 and 2036. Prescription omega-3 drugs: USD 393 mn in 2026, USD 650 mn in 2036, change +65%; Parenteral lipid emulsions: USD 98 mn in 2026, USD 179 mn in 2036, change +82%; Clinical nutrition and other: USD 55 mn in 2026, USD 104 mn in 2036, change +90%.20262036 forecastChangePrescription omega-3 drugs+65%393 mn650 mnParenteral lipid emulsions+82%98 mn179 mnClinical nutrition and other+90%55 mn104 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Prescription omega-3 drugs72.0%69.7%USD 393 mn5.2%
Parenteral lipid emulsions18.0%19.1%USD 98 mn6.2%
Clinical nutrition and other10.0%11.1%USD 55 mn6.7%

By source

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Fish oil68.0%62.0%USD 371 mn4.5%
Krill oil10.0%9.0%USD 55 mn4.4%
Algal oil14.0%20.0%USD 76 mn9.3%
Other marine and synthetic8.0%9.0%USD 44 mn6.8%

By concentration

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Low concentration grades12.0%10.0%USD 66 mn3.6%
Mid concentration grades30.0%28.0%USD 164 mn4.8%
High concentration grades38.0%38.0%USD 207 mn5.5%
Ultra-high purity grades20.0%24.0%USD 109 mn7.4%

By route

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Oral capsule grades58.0%54.0%USD 317 mn4.8%
Intravenous emulsion grades24.0%26.0%USD 131 mn6.3%
Enteral and pediatric18.0%20.0%USD 98 mn6.6%

Top 25 countries for pharmaceutical omega-3 API by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 85.0% of 2026 revenue and the 25 countries below together hold 95.5%.

Exhibit 4United States is the largest country market at USD 218 mn in 2026, and the three largest countries hold 57.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Pharmaceutical Omega-3 API market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 218 mn, 40.0%; Japan: USD 49 mn, 9.0%; China: USD 44 mn, 8.0%; Germany: USD 27 mn, 5.0%; India: USD 27 mn, 5.0%; South Korea: USD 22 mn, 4.0%; Canada: USD 22 mn, 4.0%; Italy: USD 22 mn, 4.0%; France: USD 16 mn, 3.0%; Spain: USD 16 mn, 3.0%.United States218 mn 40.0%Japan49 mn 9.0%China44 mn 8.0%Germany27 mn 5.0%India27 mn 5.0%South Korea22 mn 4.0%Canada22 mn 4.0%Italy22 mn 4.0%France16 mn 3.0%Spain16 mn 3.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 218 mn40.0%USD 357 mn5.0%
2JapanUSD 49 mn9.0%USD 73 mn4.0%
3ChinaUSD 44 mn8.0%USD 95 mn8.1%
4GermanyUSD 27 mn5.0%USD 45 mn5.1%
5IndiaUSD 27 mn5.0%USD 59 mn8.0%
6South KoreaUSD 22 mn4.0%USD 39 mn6.0%
7CanadaUSD 22 mn4.0%USD 35 mn5.0%
8ItalyUSD 22 mn4.0%USD 35 mn5.0%
9FranceUSD 16 mn3.0%USD 25 mn4.4%
10SpainUSD 16 mn3.0%USD 27 mn5.1%
11NorwayUSD 13 mn2.3%USD 21 mn4.8%
12NetherlandsUSD 7.6 mn1.4%USD 12 mn4.9%
13SwitzerlandUSD 5.6 mn1.0%USD 9.1 mn5.0%
14AustraliaUSD 4.5 mn0.8%USD 7.3 mn4.8%
15DenmarkUSD 3.8 mn0.7%USD 6.2 mn4.9%
16United KingdomUSD 3.3 mn0.6%USD 5.3 mn4.8%
17TaiwanUSD 3.0 mn0.5%USD 4.8 mn4.9%
18BrazilUSD 2.7 mn0.5%USD 6.2 mn8.7%
19ChileUSD 2.5 mn0.5%USD 4.5 mn6.2%
20PeruUSD 2.3 mn0.4%USD 5.2 mn8.6%
21IsraelUSD 2.1 mn0.4%USD 4.8 mn8.6%
22PolandUSD 2.0 mn0.4%USD 4.6 mn8.8%
23MexicoUSD 1.9 mn0.3%USD 4.3 mn8.7%
24BelgiumUSD 1.8 mn0.3%USD 2.8 mn4.8%
25TurkeyUSD 1.7 mn0.3%USD 3.8 mn8.5%
Rest of worldUSD 25 mn4.5%USD 40 mn5.1%
Exhibit 5United States and China account for 49% of the USD 387 mn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Pharmaceutical Omega-3 API market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 546 mn. United States: +USD 139 mn; China: +USD 51 mn; India: +USD 31 mn; Japan: +USD 24 mn; Germany: +USD 17 mn; 20 other countries: +USD 108 mn; Rest of world: +USD 16 mn. Market value 2036: USD 933 mn.Market value 2026546 mnUnited States+139 mnChina+51 mnIndia+31 mnJapan+24 mnGermany+17 mn20 other countries+108 mnRest of world+16 mnMarket value 2036933 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • BASF
  • KD Pharma
  • Croda
  • DSM-Firmenich

Group 2: Regional and specialist players

  • Nippon Suisan Kaisha
  • Epax
  • Chemport
  • Polaris
  • Maruha Nichiro

Group 3: Emerging and niche players

  • Solutex
  • Golden Omega

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the pharmaceutical omega-3 API market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.5% is calculated from the resulting values.

The market is divided by product, by end use, by source, by concentration, by route. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the pharmaceutical omega-3 API market?

The global pharmaceutical omega-3 API market is estimated at USD 520 mn in 2025 and USD 546 mn in 2026.

How fast will the pharmaceutical omega-3 API market grow?

It is forecast to reach USD 933 mn by 2036, a compound annual growth rate of 5.5% from 2026, an increase of USD 387 mn.

Which country is the largest market for pharmaceutical omega-3 API?

United States is the largest market by revenue at USD 218 mn in 2026, 40.0% of the global total. The three largest countries together hold 57.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 8.1% a year from 2026 to 2036.

Which pharmaceutical omega-3 API segment is largest?

In the by product split, EPA ethyl ester is the largest segment with 36.0% of 2026 revenue.

Who are the leading pharmaceutical omega-3 API companies?

Global leaders include BASF, KD Pharma, Croda, DSM-Firmenich.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Pharmaceutical Labeling Pharmaceutical Serialization →

All Healthcare markets →

Request a sample